Analyst Price Targets — RNAC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 10:16 am | — | H.C. Wainwright | $25.00 | $8.53 | TheFly | Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright |
| March 9, 2026 2:57 pm | — | Cantor Fitzgerald | $16.00 | $9.02 | TheFly | Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald |
| August 9, 2024 6:19 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $12.87 | TheFly | Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright |
| July 3, 2024 7:55 am | John Newman | Canaccord Genuity | $43.00 | $15.77 | TheFly | Cartesian Therapeutics price target raised to $43 from $38 at Canaccord |
| May 24, 2024 5:35 am | Uy Ear | Mizuho Securities | $40.00 | $25.46 | StreetInsider | Mizuho Resumes Cartesian Therapeutics (RNAC) at Buy |
Latest News for RNAC
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company's common stock with effective grant dates of August 3, 2026 and…
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company's common stock with…
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RNAC.
U.S. House Trading
No House trades found for RNAC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.